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Background: Controversy exists with regard to the impact that the different components of diagnosis delay may
have on the degree of invasion and prognosis in patients with colorectal cancer. The follow-up strategies after
treatment also vary considerably. The aims of this study are: a) to determine if the symptoms-to-diagnosis interval
and the treatment delay modify the survival of patients with colorectal cancer, and b) to determine if different
follow-up strategies are associated with a higher survival rate.
Methods/Design: Multi-centre study with prospective follow-up in five regions in Spain (Galicia, Balearic Islands,
Catalonia, Aragón and Valencia) during the period 2010-2012. Incident cases are included with
anatomopathological confirmation of colorectal cancer (International Classification of Diseases 9th revision codes
153-154) that formed a part of a previous study (n = 953).
At the time of diagnosis, each patient was given a structured interview. Their clinical records will be reviewed
during the follow-up period in order to obtain information on the explorations and tests carried out after treat-
ment, and the progress of these patients.
Symptoms-to-diagnosis interval is defined as the time calculated from the diagnosis of cancer and the first
symptoms attributed to cancer. Treatment delay is defined as the time elapsed between diagnosis and treatment.
In non-metastatic patients treated with curative intention, information will be obtained during the follow-up period
on consultations performed in the digestive, surgery and oncology departments, as well as the endoscopies,
tumour markers and imaging procedures carried out.
Local recurrence, development of metastases in the follow-up, appearance of a new tumour and mortality will be
included as outcome variables.
Actuarial survival analysis with Kaplan-Meier curves, Cox regression and competitive risk survival analysis will be
performed.
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reproduction in any medium, provided the original work is properly cited.Discussion: This study will make it possible to verify if the different components of delay have an impact on
survival rate in colon cancer and rectal cancer. In consequence, this multi-centre study will be able to detect the
variability present in the follow-up of patients with colorectal cancer, and if this variability modifies the prognosis.
Ideally, this study could determine which follow-up strategies are associated with a better prognosis in colorectal
cancer.
Background
In Spain, colorectal cancer is responsible for 12.6% of all
deaths as a result of cancer in men, and 15.1% in
women, according to data from 2007, representing the
second most important tumour location in men and
women [1]. It is estimated that in our country around
22,000 new cases are detected each year, with 13,500
deaths [2]. Survival of colorectal cancer at 5 years,
according to data from EUROCARE 4 for cases diag-
nosed between 2000 and 2002, is 61.5% [3]. The survival
rate is slightly higher amongst women than men, and in
the location in the colon compared to the rectum [4]. In
recent years, a 2% increase in the global survival rate
has been recorded in Spain [5].
Colorectal cancer is usually diagnosed from clinical
manifestations, as a result of a screening programme, or
as a chance finding. Between the start of the illness and
its diagnosis or treatment, there is a variable period of
time known as diagnosis delay. Diagnosis delay may be
affected by the characteristics of the illness, the charac-
teristics of the patient, and the characteristics of the
healthcare system. Studies carried out in our country
reveal that the period of time between the appearance
of the first symptoms and the first consultation in color-
ectal cancer is a median of 49 days [6].
Different factors associated with the patient or the
healthcare system have been identified as modifiers of
diagnosis delay [7-12]. Not recognising the severity
of the symptoms, low socio-economic level, the location
of the tumour, diagnostic errors and the application of
inadequate tests or ones with previously negative results
may all increase the delay. The factors associated with a
shorter diagnosis delay include: associated comorbidity,
visiting the hospital directly, or the use of derivation
protocols. There is no clear evidence with regard to fac-
tors such as the patient’sa g eo rs e x ,t h ef e a ro fb e i n g
diagnosed with cancer, the existence of pain, educational
level or family history. Neither is there any evidence that
the frequency of use of the healthcare system by the
patient or the use of fast access to endoscopies reduces
diagnosis delay.
It appears reasonable to consider that reducing the
delay could allow for diagnosis in earlier stages of the
illness, and therefore improve the prognosis. However,
the results are contradictory [13-20], as it has even been
indicated that greater diagnosis delay is associated with
a better prognosis [19] or that the delay is not asso-
ciated with the stage or prognosis [18]. Two recent
reviews made by members of this team reveal that there
is controversy with regard to the role that delay plays in
relation to the survival rate and degree of invasion in
the diagnosis of colorectal cancer [21,22].
Once the tumour is diagnosed, the follow-up protocol
for patients with cancer of the colon and rectum may
modify the prognosis. The ideal recommendations in
the follow-up process have yet to be described [23]. Dif-
ferent meta-analyses have been carried out on the
effects of the follow-up on the prognosis of cancer of
the colon and rectum [24-29]. The results of these
meta-analyses coincide in that global survival is higher
amongst patients who followed an intensive programme
with respect to those who did not, and no improvement
was seen in the specific survival rate. The survival rate
was higher for those who used detection techniques
such as tomography and carcinoembryonic antigen
(CEA) determinations [25,26]. Intensive follow-up was
associated with earlier detection of recurrences, the
detection of recurrences susceptible to surgical resection
and the probability of curative resection [26,27].
These follow-up programmes include frequent medical
check-ups, CEA determinations, radiological studies of
the thorax, abdominal ecography or tomography, and
colonoscopy. However, the ideal frequency for carrying
out these tests or the type of tests to be applied is not
clear. The hypothesis is therefore focused on the fact
that improvement in the survival rate in patients with
curative surgery is due, amongst other factors, to the
diagnosis of recurrence in early and asymptomatic stages
that permit the curative resection of the recurrence. As
a result, controversy exists with regard to the frequency
at which these patients should be seen, which tests
should be carried out, and if different follow-up strate-
gies have an impact on the patient’s progress [26].
Continuing on from the previous study [30], which
allowed us to identify a cohort of 953 patients with col-
orectal cancer, we consider it to be of paramount inter-
est to determine which variables from amongst those
studied, as well as the different components of diagnosis
delay, affect the prognosis of patients with cancer of the
colon and rectum.
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Main objectives
▪ To determine if the symptoms-to-diagnosis interval
and the treatment delay modify the survival rate of
patients with cancer of the colon and rectum.
▪ To determine in patients with non-metastatic color-
ectal cancer treated with curative intention, if different
follow-up strategies are associated with a higher survival
rate.
Secondary objectives
▪ To determine in patients with colorectal cancer:
a) The global survival rate.




▪ From amongst the variables included in this study,
to determine those which modify the prognosis in
patients with colorectal cancer.
▪ To determine, in patients with non-metastatic color-
ectal cancer treated with curative intention, if different
follow-up strategies are associated with a lower rate of
local recurrence, the detection of asymptomatic recur-
rence, the detection of hepatic metastasis, and the rate
of operable recurrences and metachronous tumours.
▪ To describe the variability in the follow-up of cancer
of the colon and rectum according to the particular
autonomous region and hospital, in terms of the types
of tests used, the frequency at which the tests are used,
and the specialist who carries out the follow-up.
Methods/Design
Multi-centre prospective follow-up study in five regions
of Spain (Galicia, Balearic Islands, Catalonia, Valencia
and Aragón) during the period 2010-2012. It includes
incident cases with anatomopathological confirmation of
colorectal cancer according to the International Classifi-
cation of Diseases (ICD) 9th revision (codes 153 and
154) which were included in the previous study [30]
(n = 953). Prevalent or recurrent cases were excluded,
together with cases of multiple cancer, cases that were
only dealt with in private hospitals, cases detected
through colorectal cancer screening, and cases diag-
nosed in another hospital but which were referred for
treatment to the hospitals included in the study.
Measurements
Information obtained from the previous study is available
for each patient, which included variables related to the
patient, the tumour (site, histological grade, TNM stage),
clinical symptoms, delay intervals and characteristics of
the health system in each of the regions studied [30]. Each
of the patients was interviewed at the time of the diagnosis
using a structured questionnaire. During the follow-up
period, clinical records will be reviewed and surveillance
of the outcomes of interest will be investigated.
The measurements that will be recorded on each
patient at the time of diagnosis and during the follow-
up can be found in Additional file 1: Table S1. Patients’
variables include age, gender, civil status, educational
level, family history of cancer, symptoms perception and
the Charlson comorbidity index at the time of diagnosis.
Tumour characteristics include: site (according to
ICD-9
th), tumour size, histological grade, TNM stage
at diagnosis, location of metastases and infiltration of
adjacent organs.
The symptoms-to-diagnosis interval is defined as the
time elapsed from the date the patient perceived the
first symptoms until the cytohistological confirmation of
the diagnosis of cancer (date of biopsy or direct sur-
gery). This delay has two components: patient delay and
diagnosis delay (Table 1). Treatment delay is defined as
the time elapsed between diagnosis and treatment. In
this context we consider surgical treatment.
During the follow-up, the variables studied will be:
a) Type of treatment: in the surgical procedure we
will investigate the type of resection, the need for a
stent endoprosthesis and whether a colostomy is
required or not. We will also take into account if
planned or emergency surgery is performed, the
curative or palliative intention of the surgery, the
anastomosis technique, and if laparoscopic, open
colorectal surgery, transanal resection and/or endo-
scopic resection is performed, as well as the need for
reinterventions after the initial surgery.
The need and completion of chemotherapy and
radiation therapy sessions will also be recorded.
b) Hospital consultations related to the colorectal
cancer and exploratory procedures: in this section
we account for the number of visits to the specialists
(surgeons, digestive disease specialists and oncolo-
gists) and the diagnostic investigation procedures
after the surgery. This information will be only col-
lected on patients with non-metastatic colorectal
cancer with curative intention. Among the diagnostic
procedures, we consider imaging examinations (eco-
graphies, positron emission tomographies, computed
tomographies, magnetic resonances), endoscopy
explorations (colonoscopies, rectoscopies) and car-
cionoembryonic antigen (CEA) determinations.
c) Presence of incidents in the follow-up:a so u t -
come variables will be included local recurrence,
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ance of a new tumour and mortality. The mortality
records from each autonomous region will be used
to determine the death of the patients and the cause,
also determining whether the cause of death is asso-
ciated with the colorectal cancer or not.
Sample size
This study includes n = 953 patients. As we have two
working hypotheses, one connected with diagnosis delay
and another connected with the follow-up strategies, we
will justify the sample size in order to deal with each of
the hypotheses.
This sample size will make it possible to detect as sig-
nificant, in a Cox regression model, a relative risk of 1.3
or more associated with greater delay, assuming an
exposure to this possibility of 50% and a censored data
percentage of 50% (Security: 95%; Statistical power:
80%). Assuming an exposure prevalence of 50% maxi-
mises the sample size necessary to detect a relative risk
of this magnitude. In terms of the censoring value, we
have estimated it at 50%, as according to published data
[3] the estimated survival rate at five years for colorectal
cancer in Spain is 61.2%. In this situation, the sample
size required to estimate a relative risk of 1.3 or more
(a = 0.05, b = 0.2) would be n = 912 patients.
Also, according to a revision of the Cochrane Library
[31], proof was found that there are benefits for the glo-
bal survival rate at five years for patients with colorectal
cancer subjected to a more intensive follow-up (OR =
0.73; 95% IC = 0.59-0.91). This OR = 0.73 implies that
patients without exhaustive follow-up would have a
greater risk of death (1/0.73 = 1.4). In order to deal with
the second objective, only patients with non-metastatic
cancer receiving surgery with curative intention will be
included. According to the data analysed so far for this
cohort, approximately 17% of the patients would have a
metastatic tumour, meaning that for the second objec-
tive 830 patients would be included. This sample size
will make it possible to detect a risk of 1.4, with a cen-
soring and exhibition percentage of 50%, and with the
same security and power as in the previous case.
Statistical analysis
Descriptive analyses will be performed for all variables.
Continuous variables will be reported using means ±
standard deviations (SD) or median (interquartile range).
For dichotomous/categorical variables, absolute numbers
and percentages will be computed, together with its 95%
confidence intervals.
The comparison of means will be carried out using Stu-
dent’s t test, Mann-Whitney test, analysis of variance or
the Kruskall-Wallis test as appropriate. The association
of qualitative variables will be carried out using Chi-
square statistics. The correlation among quantitative vari-
ables will be assessed using Spearman’s correlation
coefficient.
Actuarial survival analysis with Kaplan-Meier curves,
log-rank test and Cox regression analysis will be per-
formed. The assumption of hazards proportionality will
be assessed using different procedures: a) a log-minus-
log survival plot for each covariate, b) by analysis of
scaled Schoenfeld residuals and c) by tests of interaction
between categorized variables and time in the Cox
model.
In case of violation of the hazard proportionality
assumption for any of the covariates, an interaction
term between that covariate and time will be included
in the Cox regression model. Additionally, survival
regression models using B-spline functions will be
explored to model non-proportional hazards. These
computations will be performed by using the functions
available in the survival package in R (version 2.10.0).
Due to the fact that Kaplan-Meier method could over-
estimate the incidence of the events in the follow-up, a
competitive mortality risk survival analysis will also be
considered [32,33].
The analysis of the specific survival, progression-free
survival and relapse-free survival rate will be carried out
i nas i m i l a rw a yt ot h ea n a l y s i so ft h eg l o b a ls u r v i v a l
rate. A similar analysis will be carried out to compare
the prognosis of non-metastatic colorectal cancer sub-
jected to surgery with curative intention according to
the follow-up strategy.
The accuracy of different variables to predict events in
the follow-up will be evaluated using the C-index [34].
Sensitivity, specificity and predictive values, with their
95% confidence intervals, will be determined for differ-
ent cutoffs.
Two-sided tests will be used, and p-values < 0.05 will
be considered as statistically significant. Statistical ana-
lyses will be performed using SPSS for Windows (ver-
sion 17.0, SPSS Inc., Chicago, Illinois) and R (version
2.10.0).
A p a r tf r o mp e r f o r m i n ga na n a l y s i so fa l lo ft h e
patients, the patients with colon cancer and patients
with rectal cancer will be analysed independently.
Ethical and legal issues
The study will be carried out according to the good
clinical practice guidelines of the Helsinki declaration.
Informed consent was obtained from each patient to
take part in the study and to review their clinical
records. This project was approved by the ethics review
board of each one of the sites participating in the study:
Clinical Research Ethical Committee of Galicia (decision
no. 2009/110), Clinical Research Ethical Committee of
Fernández et al. BMC Cancer 2010, 10:528
http://www.biomedcentral.com/1471-2407/10/528
Page 4 of 6Illes Balears (decision no. 1167/09 PI), Clinical Research
Ethical Committee of the Municipal Institute of Health
Care (CEIC-IMAS, Barcelona) (decision no. 2009/3556/
I), Clinical Research Ethical Committee of Aragón (deci-
sion no. 06/2009), and the Clinical Research Ethical
Committee of the University Clinic Hospital of Valencia
(date of approval June 5,2009).
Discussion
Systematic reviews regarding the relationship between
diagnosis delay and the degree of invasion and survival
in colorectal cancer reveal the need to investigate this
issue with larger samples of patients, and to analyse
colon cancer and rectal cancer independently [21,22].
Some of the studies reviewed use specific stages or oper-
able cases amongst their inclusion criteria, which intro-
duce bias into the selection process and make it
impossible to determine the relationship between the
delay and the different stages in the diagnosis of color-
ectal cancer. Another problem that was observed was
that in the majority of the studies, survival was calcu-
lated from the diagnosis or intervention date, instead of
the date when the symptoms began, which could result
in lead-time bias. These problems were taken into
account in the protocol used in our study, where an
independent analysis will be carried out depending on
the location of the cancer in a cohort of nearly 1000
patients. This will include all of the incident cases diag-
nosed consecutively during the study period, which
includes five different regions in the country. The study
has excluded patients detected by screening and preva-
lent or recurrent cases, as in these cases the delay inter-
vals are different. The study also excludes patients
treated in private hospital, as in Spain the whole of the
population is covered by the public health system.
The majority of studies use survival analysis strategies
with the methodology of Kaplan and Meier. As this
methodology may lead to overestimating the likelihood
of the events of interest occurring, we propose a compe-
titive risk analysis to study the prognosis of these
patients [32,33].
Also, with regard to the follow-up strategies for
patients with colorectal cancer, the ideal recommenda-
tions for this process have yet to be described [23]. These
recommendations refer to the opinions of experts who
indicate the performance of different examinations dur-
ing the follow-up period [35,36]. Endoscopic techniques
are the most frequently used, and imaging methods are
the least used, with considerable variability amongst the
different experts consulted [23]. Variability also exists
depending on the geographic location of the experts con-
sulted [37]. Other authors indicate that surveillance after
potentially curative colon cancer surgery is not signifi-
cantly affected by the geographic location of the surgeon
who performs the surveillance testing, and only modestly
affected by the population size of the metropolitan area
in which he/she practices [31]. Carrying out multi-centre
studies such as the one we propose, which studies varia-
bility in clinical practice in different regions of the same
country, will provide more detailed information on its
impact on the prognosis of these patients.
Additional material
Additional file 1: Table S1, Study measurements. Table displaying the
measurements that will be recorded on each patient at the time of
diagnosis and during the follow-up.
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